These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 24892795)

  • 1. Improved testing of recent HIV-1 infections with the BioRad avidity assay compared to the limiting antigen avidity assay and BED Capture enzyme immunoassay: evaluation using reference sample panels from the German Seroconverter Cohort.
    Hauser A; Santos-Hoevener C; Meixenberger K; Zimmermann R; Somogyi S; Fiedler S; Hofmann A; Bartmeyer B; Jansen K; Hamouda O; Bannert N; Kuecherer C
    PLoS One; 2014; 9(6):e98038. PubMed ID: 24892795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of recent HIV-1 infection using a new limiting-antigen avidity assay: potential for HIV-1 incidence estimates and avidity maturation studies.
    Duong YT; Qiu M; De AK; Jackson K; Dobbs T; Kim AA; Nkengasong JN; Parekh BS
    PLoS One; 2012; 7(3):e33328. PubMed ID: 22479384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of HIV subtype on performance of the limiting antigen-avidity enzyme immunoassay, the bio-rad avidity assay, and the BED capture immunoassay in Rakai, Uganda.
    Longosz AF; Serwadda D; Nalugoda F; Kigozi G; Franco V; Gray RH; Quinn TC; Eshleman SH; Laeyendecker O
    AIDS Res Hum Retroviruses; 2014 Apr; 30(4):339-44. PubMed ID: 24083837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating False-Recent Classification for the Limiting-Antigen Avidity EIA and BED-Capture Enzyme Immunoassay in Vietnam: Implications for HIV-1 Incidence Estimates.
    Shah NS; Duong YT; Le LV; Tuan NA; Parekh BS; Ha HTT; Pham QD; Cuc CTT; Dobbs T; Tram TH; Lien TTX; Wagar N; Yang C; Martin A; Wolfe M; Hien NT; Kim AA
    AIDS Res Hum Retroviruses; 2017 Jun; 33(6):546-554. PubMed ID: 28193090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of a limiting-antigen avidity enzyme immunoassay for cross-sectional estimation of HIV incidence in the United States.
    Konikoff J; Brookmeyer R; Longosz AF; Cousins MM; Celum C; Buchbinder SP; Seage GR; Kirk GD; Moore RD; Mehta SH; Margolick JB; Brown J; Mayer KH; Koblin BA; Justman JE; Hodder SL; Quinn TC; Eshleman SH; Laeyendecker O
    PLoS One; 2013; 8(12):e82772. PubMed ID: 24386116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a New Limiting-Antigen Avidity Dot Immuno-Gold Filtration Assay for HIV-1 Incidence.
    Gao Z; Yan H; Feng X; Wu L; Qiu M; Xing W; Zhang G; Zhang Z; Jiang Y
    PLoS One; 2016; 11(8):e0161183. PubMed ID: 27513563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the Performance of Three Biomarker Assays for Recent HIV Infection Using a Well-Characterized HIV-1 Subtype C Incidence Cohort.
    Gonese E; Kilmarx PH; van Schalkwyk C; Grebe E; Mutasa K; Ntozini R; Parekh B; Dobbs T; Duong Pottinger Y; Masciotra S; Owen M; Nachega JB; van Zyl G; Hargrove JW
    AIDS Res Hum Retroviruses; 2019 Jul; 35(7):615-627. PubMed ID: 30938164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recalibration of the limiting antigen avidity EIA to determine mean duration of recent infection in divergent HIV-1 subtypes.
    Duong YT; Kassanjee R; Welte A; Morgan M; De A; Dobbs T; Rottinghaus E; Nkengasong J; Curlin ME; Kittinunvorakoon C; Raengsakulrach B; Martin M; Choopanya K; Vanichseni S; Jiang Y; Qiu M; Yu H; Hao Y; Shah N; Le LV; Kim AA; Nguyen TA; Ampofo W; Parekh BS
    PLoS One; 2015; 10(2):e0114947. PubMed ID: 25710171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of natural and ARV-induced viral suppression and viral breakthrough on anti-HIV antibody proportion and avidity in patients with HIV-1 subtype B infection.
    Wendel SK; Mullis CE; Eshleman SH; Blankson JN; Moore RD; Keruly JC; Brookmeyer R; Quinn TC; Laeyendecker O
    PLoS One; 2013; 8(2):e55525. PubMed ID: 23437058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating HIV incidence in the Akwa Ibom AIDS indicator survey (AKAIS), Nigeria using the limiting antigen avidity recency assay.
    Negedu-Momoh OR; Balogun O; Dafa I; Etuk A; Oladele EA; Adedokun O; James E; Pandey SR; Khamofu H; Badru T; Robinson J; Mastro TD; Torpey K
    J Int AIDS Soc; 2021 Feb; 24(2):e25669. PubMed ID: 33619853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune responses in Ugandan women infected with subtypes A and D HIV using the BED capture immunoassay and an antibody avidity assay.
    Longosz AF; Morrison CS; Chen PL; Arts E; Nankya I; Salata RA; Franco V; Quinn TC; Eshleman SH; Laeyendecker O
    J Acquir Immune Defic Syndr; 2014 Apr; 65(4):390-6. PubMed ID: 24583613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Field Validation of Limiting-Antigen Avidity Enzyme Immunoassay to Estimate HIV-1 Incidence in Cross-Sectional Survey in Swaziland.
    Duong YT; Dobbs T; Mavengere Y; Manjengwa J; Rottinghaus E; Saito S; Bock N; Philip N; Justman J; Bicego G; Nkengasong JN; Parekh BS
    AIDS Res Hum Retroviruses; 2019 Oct; 35(10):896-905. PubMed ID: 31204867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The concordance of the limiting antigen and the Bio-Rad avidity assays in persons from Estonia infected mainly with HIV-1 CRF06_cpx.
    Huik K; Soodla P; Pauskar M; Owen SM; Luo W; Murphy G; Jõgeda EL; Kallas E; Rajasaar H; Avi R; Masciotra S; Lutsar I;
    PLoS One; 2019; 14(5):e0217048. PubMed ID: 31125356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decision tree for accurate infection timing in individuals newly diagnosed with HIV-1 infection.
    Verhofstede C; Fransen K; Van Den Heuvel A; Van Laethem K; Ruelle J; Vancutsem E; Stoffels K; Van den Wijngaert S; Delforge ML; Vaira D; Hebberecht L; Schauvliege M; Mortier V; Dauwe K; Callens S
    BMC Infect Dis; 2017 Nov; 17(1):738. PubMed ID: 29187159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and Evaluation of a Modified Fourth-Generation Human Immunodeficiency Virus Enzyme Immunoassay for Cross-Sectional Incidence Estimation in Clade B Populations.
    Kirkpatrick AR; Patel EU; Celum CL; Moore RD; Blankson JN; Mehta SH; Kirk GD; Margolick JB; Quinn TC; Eshleman SH; Laeyendecker O
    AIDS Res Hum Retroviruses; 2016 Aug; 32(8):756-62. PubMed ID: 26988426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential specificity of HIV incidence assays in HIV subtypes A and D-infected individuals from Rakai, Uganda.
    Mullis CE; Munshaw S; Grabowski MK; Eshleman SH; Serwadda D; Brookmeyer R; Nalugoda F; Kigozi G; Kagaayi J; Tobian AA; Wawer M; Gray RH; Quinn TC; Laeyendecker O
    AIDS Res Hum Retroviruses; 2013 Aug; 29(8):1146-50. PubMed ID: 23641870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specificity of four laboratory approaches for cross-sectional HIV incidence determination: analysis of samples from adults with known nonrecent HIV infection from five African countries.
    Laeyendecker O; Brookmeyer R; Mullis CE; Donnell D; Lingappa J; Celum C; Baeten JM; Campbell MS; Essex M; de Bruyn G; Farquhar C; Quinn TC; Eshleman SH;
    AIDS Res Hum Retroviruses; 2012 Oct; 28(10):1177-83. PubMed ID: 22283149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the false recent classification rates of multiassay algorithms in estimating HIV type 1 subtype C incidence.
    Moyo S; LeCuyer T; Wang R; Gaseitsiwe S; Weng J; Musonda R; Bussmann H; Mine M; Engelbrecht S; Makhema J; Marlink R; Baum MK; Novitsky V; Essex M
    AIDS Res Hum Retroviruses; 2014 Jan; 30(1):29-36. PubMed ID: 23937344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of cross-sectional HIV incidence assay results from dried blood spots and plasma.
    Schlusser KE; Pilcher C; Kallas EG; Santos BR; Deeks SG; Facente S; Keating SM; Busch MP; Murphy G; Welte A; Quinn T; Eshleman SH; Laeyendecker O
    PLoS One; 2017; 12(2):e0172283. PubMed ID: 28231277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of a BioRad Avidity assay for identification of recent HIV-1 infections using dried serum or plasma spots.
    Hauser A; Heiden MA; Meixenberger K; Han O; Fiedler S; Hanke K; Koppe U; Hofmann A; Bremer V; Bartmeyer B; Kuecherer C; Bannert N
    J Virol Methods; 2019 Apr; 266():114-120. PubMed ID: 30738741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.